Corey Davis

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) reported Tuesday its second-quarter results along with a series of updates concerning ongoing clinical trials and when investors can expect top-line data. Zynerba was expected to release phase 2 STAR 1 trial data of its ZYN002 for the treatment of adult...

Shares of Cara Therapeutics Inc (NASDAQ: CARA) fell nearly 30 percent early Friday morning after the company released concerning top-line results from a phase 2B trial of its oral CR845 therapy for the treatment of pain associated with osteoarthritis of the hip or knee. But not all analysts are...

Aerie Pharmaceuticals Inc (NASDAQ: AERI) shares were seen up over 29 percent Thursday after the company reported positive Phase III trial data on its glaucoma treatment candidate, Roclatan. According to the company, Roclatan achieved the primary efficacy endpoint in demonstrating superiority over...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) announced that the read out from its Phase 2 studies for ZYN002, STAR 1 (in epilepsy) and STOP (in osteoarthritis pain), would be available in July or August, with the epilepsy data expected first. H.C. Wainwright’s Corey Davis maintained a Buy...

H.C. Wainwright reiterated its Buy rating on Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) after the company updated on its three P2 clinical programs utilizing ZYN002, its topical gel formulation of cannabidiol (CBD) at its analyst day. The company said all the three programs would now be...

Shares of Ophthotech Corp (NASDAQ: OPHT) tanked more than 80 percent on Monday after the company announced that the primary endpoint in two Phase 3 trials exploring its Fovista® therapy was not met. Fovista is Ophthotech's therapy intended to be administered in combination with an anti VEGF agent...

On September 30, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced Phase 2 results for rinucumab, with the drug not meeting the primary endpoint of the study. On December 12, Ophthotech Corp (NASDAQ: OPHT) announced Phase 3 results for Fovista, which also did not achieve the primary...

H.C. Wainwright reiterated its Buy rating on Kite Pharma Inc (NASDAQ: KITE) on expectations that its cancer drug KTE-C19 would be approved in 2017 given more granular data on hand. “Given that KTE-C19 has demonstrated positive results in DLBCL (including relapsed and refractory subgroups),...

H.C. Wainwright’s Corey Davis expressed optimism regarding Cara Therapeutics Inc (NASDAQ: CARA)'s CR845, which could be one of the first kappa opioid receptor agonists that does not enter the central nervous system and therefore has potential to treat peripheral pain without leading to...

Shares of Lipocine Inc (NASDAQ: LPCN), a specialty pharmaceutical company that focuses on developing products in the are of men's and women's health, has seen its stock rise nearly 40 percent over the past two weeks. September 26: Positive Top-Line Results The company announced...

H.C. Wainwright’s Corey Davis believes that what differentiates Lipocine Inc (NASDAQ: LPCN) from its competitors is the company’s oral drug delivery technology, called “Lip’ral”. Davis initiated coverage of the company with a Buy rating and price target of $25....

HC Wainwright has started coverage of vTv Therapeutics Inc (NASDAQ: VTVT) with a Buy rating and $13 price target on the potential success of its three late-stage drugs, especially the two diabetic compounds. In fact, the brokerage expects the diabetes compounds to be more likely to move the stock...

In a report issued Monday, Canaccord analysts Corey Davis and Lidia Liu initiated coverage on shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) with a Buy rating. The experts set a $35.00 price target for the stock. The company is differentiated by its synthetic manufacturing and transdermal...